This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.COHORT is an observational trial designed to collect prospective data from individuals who are part of a Huntington's disease (HD) family. Subjects will either be clinically diagnosed with HD, be a positive gene carrier, or be at-risk for inheritance/have an unknown gene status. Family members who have no HD family history (spouses) and/or gene negative status are also eligible to participate. For individuals under age 18, only those with clinically diagnosed features of HD in conjunction with a positive gene test will be eligible to participate. There is no limit on the number of eligible subjects.Study visits occur annually. Baseline procedures include: Unified Huntington's Disease Rating Scale 99 (UHDRS 99), Mini-Mental State Examination (MMSE), physical and neurological examinations, medical and concomitant medication history. All subjects 18 years of age and older will have a single blood specimen collected to obtain the subject's genotype/CAG repeat number. Optional procedures available at baseline for subjects 18 years of age and older include the completion of a Family History Questionnaire (FHQ) and the collection of blood and urine samples in a specimen repository for future research in HD. Annual study visits include: UHDRS 99; MMSE; medical examination; changes in concomitant medications and previous medical history. If the subject agreed to participate in the FHQ at baseline, the subject will be asked to provide information about new deaths and onsets of HD. If the subject agreed to participate in the optional blood and urine samples for repository storage, these samples will be collected.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000750-35
Application #
7606478
Study Section
Special Emphasis Panel (ZRR1-CR-8 (01))
Project Start
2006-12-01
Project End
2007-11-30
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
35
Fiscal Year
2007
Total Cost
$1,198
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4
Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Patel, Yash R; Kirkman, M Sue; Considine, Robert V et al. (2017) Retinopathy predicts progression of fasting plasma glucose: An Early Diabetes Intervention Program (EDIP) analysis. J Diabetes Complications 31:605-610
Robarge, Jason D; Metzger, Ingrid F; Lu, Jessica et al. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrob Agents Chemother 61:

Showing the most recent 10 out of 767 publications